Table 1 Summary of Clinical, Pathologic and Genetic Characteristics of Tumors
From: KRAS mutation in secondary malignant histiocytosis arising from low grade follicular lymphoma
Timeline | Location | Diagnosis | Immunophenotype of Neoplastic Cells | Key FISH/Molecular Characteristics | Therapy |
|---|---|---|---|---|---|
Year 1 | Neck mass | FL (Fig. 1) | CD19+, CD10+, CD5-, surface lambda restricted | NA | Radiation |
Year 3 | Lung and bone marrow | Lung: DLBCL Bone marrow: FLÂ (Fig. 2) | Lung: CD20+, CD10+ Bone marrow: CD19+, CD10+, CD5-, surface lambda restricted | NA | R-CHOP |
Year 9 | Skin and breast | FL (Fig. 3) | CD20+, CD10+, BCL6+, BCL2+ | IgH/BCL2 fusion KRAS wildtype MYC extra copies; no MYC rearrangement | R-Bendamustine |
Year 10 | Inguinal lymph node | LCS (Fig. 4) | CD45+, CD43+, CD1a+, S100+, CD20-, PAX5-, CD19-, CD79a-, CD10-, BCL6+ (focal) | IgH/BCL2 fusion KRAS p.G13D MYC extra copies; no MYC rearrangement | ICE, ibrutinib |
Year 10 | Ear mass | DLBCL | CD20+, CD10+, CD1a-, S100- | NA | Palliative radiation therapy |